Abstract

Objective To retrospectively analyze the results of prenatal diagnoses of noninvasive prenatal screening- (NIPS) positive pregnant women and discuss whether there is a need for chromosomal microarray analysis (CMA). Methods The study recruited 1,019 NIPS-positive women from two prenatal diagnostic centers. Based on clinical advice, they opted for traditional karyotype analysis or CMA. Single nucleotide polymorphism array testing was performed on a commercial 750K microarray chip (Affymetrix CytoScan 750K Array). Results Of the NIPS-positive women, 761 (74.7%) accepted the prenatal diagnosis. There were 418 (54.9%) abnormal results, and most (99.5%) were chromosome aneuploidy or structural abnormalities. Only three cases were confirmed as pathogenic copy number variation (CNVs), which were found only with CMA and not by karyotype analysis. Fifteen women were variants of uncertain significance (VUS) CNV. In addition, 300 women selected opted for both karyotype analysis and CMA for prenatal diagnosis: in 275 (91.7%) cases, the results of the two modalities were consistent, while in the remaining 25, they were not. In three cases, the additional positive results obtained with CMA were potentially clinically significant. Conclusions CMA may not be useful for many women positive for trisomy 21/18/13 based on NIPS results, because traditional karyotype analysis can identify most problems. However, it can yield important additional findings in women positive for fetal sex chromosome aneuploidy (SCA). Further clinical studies are needed to confirm these findings.

Highlights

  • Noninvasive prenatal screening (NIPS) is widely used to screen for trisomies 21 (T21), 18 (T18), and 13 (T13) and shows high accuracy and a low rate of false positives [1,2,3,4]

  • As a preliminary discussion of this interesting question, this study examined the clinical data of 761 NIPS-positive women who accepted the prenatal diagnosis and underwent traditional karyotype analysis or chromosomal microarray analysis (CMA) testing to generate clinical data to guide the choice of prenatal diagnostic methods

  • According to the NIPS results, they were divided into four groups: T21/T18/T13 aneuploidy (428 cases), fetal sex chromosome aneuploidy (SCA) abnormalities (411 cases), gain of another chromosome (124 cases), and chromosome loss

Read more

Summary

Introduction

Noninvasive prenatal screening (NIPS) is widely used to screen for trisomies 21 (T21), 18 (T18), and 13 (T13) and shows high accuracy and a low rate of false positives [1,2,3,4]. NIPS is already widely used as a first-line screening test in some countries. NIPS is mainly used to screen women determined as being at intermediate risk based on serological screening, or as an alternative screening test for women at high risk, or of advanced maternal age, who reject invasive prenatal diagnostic tests. As both a first- and second-line screening test, NIPS is becoming an increasingly important and effective prenatal screening approach for fetal genetic diseases

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call